Patents Represented by Attorney, Agent or Law Firm Peter G. Carroll
-
Patent number: 6258319Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: September 4, 1998Date of Patent: July 10, 2001Assignee: Cerus CorporationInventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
-
Patent number: 6218100Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5′-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.Type: GrantFiled: July 24, 1997Date of Patent: April 17, 2001Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 6017691Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: February 9, 1996Date of Patent: January 25, 2000Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 6004741Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 4' and 5' primary aminoalkyl psoralens are photoactivated in platelet preparations to inactivate pathogens.Type: GrantFiled: October 23, 1997Date of Patent: December 21, 1999Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 5908742Abstract: Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including essentially magnesium free synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.Type: GrantFiled: August 5, 1996Date of Patent: June 1, 1999Assignee: Cerus CorporationInventors: Lily Lin, Laurence Corash, Jean Marc Payrat
-
Patent number: 5712085Abstract: Psoralen compounds are synthesized which have substitutions on the 4,4',5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. Also disclosed are compositions comprising 4' or 5'-primary amino substituted psoralens in a synthetic media.Type: GrantFiled: June 5, 1995Date of Patent: January 27, 1998Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
-
Patent number: 5691132Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes. In particular, quinacrine mustard is used to inactivate pathogens in red cell compositions with retention of red cell function.Type: GrantFiled: November 14, 1994Date of Patent: November 25, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, David Cook, Aileen Nerio
-
Patent number: 5683661Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.Type: GrantFiled: June 7, 1995Date of Patent: November 4, 1997Assignee: Cerus CorporationInventors: David P. Hearst, George D. Cimino, John E. Hearst, Stephen T. Isaacs
-
Patent number: 5665762Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 5, 1995Date of Patent: September 9, 1997Assignee: Carus CorporationInventors: Peter G. Carroll, Stephen T. Isaacs, George D. Cimino
-
Patent number: 5659050Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 5, 1995Date of Patent: August 19, 1997Assignee: Cerus CorporationInventors: Stephen T. Isaacs, George D. Cimino
-
Patent number: 5654443Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: May 31, 1995Date of Patent: August 5, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
-
Patent number: 5625079Abstract: Synthesis of 4,8-dialkyl-4'-bromomethyl-5'-methylpsoralen and 4,8-dialkyl-5'-bromomethyl-4'-methylpsoralen compounds useful as intermediates.Type: GrantFiled: June 5, 1995Date of Patent: April 29, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
-
Patent number: 5618662Abstract: Intravenous administration of 8-methoxypsoralen is disclosed, and more specifically intravenous administration of 8-methoxypsoralen-blood preparations, including platelets. Random donor platelet bags are treated, stored and pooled prior to transfusion.Type: GrantFiled: January 21, 1994Date of Patent: April 8, 1997Assignee: Cerus CorporationInventors: Lily Lin, Laurence Corash
-
Patent number: 5593823Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: November 14, 1994Date of Patent: January 14, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
-
Patent number: 5582994Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 5, 1995Date of Patent: December 10, 1996Assignee: Steritech, Inc.Inventors: Peter G. Carroll, Stephen T. Isaacs, George D. Cimino
-
Patent number: 5578736Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.Type: GrantFiled: May 31, 1995Date of Patent: November 26, 1996Assignee: Steritech, Inc.Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann
-
Patent number: 5565320Abstract: A quality control assay to verify adequate treatment of blood product following decontamination with furocoumarins and light. The methods involve measuring the inhibition of template-dependent enzymatic synthesis of nucleic acid following the addition of compounds that add covalently to nucleic acid.Type: GrantFiled: October 4, 1993Date of Patent: October 15, 1996Assignee: Steritech, Inc.Inventors: George D. Cimino, Lily Lin
-
Patent number: 5559250Abstract: Novel compounds for photodecontaminating biological material which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 5, 1995Date of Patent: September 24, 1996Assignee: Steritech, Inc.Inventors: David Cook, Susan Wollowitz, Aileen Nerio
-
Patent number: 5556993Abstract: Psoralen compounds are synthesized which have substitutions on the 4,4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.Type: GrantFiled: June 5, 1995Date of Patent: September 17, 1996Assignee: Steritech, Inc.Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans P. Spielmann, Aileen Nerio
-
Patent number: 5556958Abstract: The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.Type: GrantFiled: June 3, 1994Date of Patent: September 17, 1996Assignee: Steritech, Inc.Inventors: Peter G. Carroll, Stephen T. Isaacs, George D. Cimino